Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL5031 Target Snapshot

Beta-lactamase · SINGLE PROTEIN · Pseudomonas aeruginosa (strain ATCC 15692 / PAO1 / 1C / PRS 101 / LMG12228)

Back to Search Search this target Browse approvals Evidence Card
122Compounds
95Assays
5Approved Drugs
102.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Beta-lactamase shows approved-linked disease relevance led by infection. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P24735. Start with infection, then reuse UniProt P24735 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with infection, then reuse UniProt P24735 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 1 linked drug
Open source guide
Disease program
infection

Beta-lactamase shows approved-linked disease relevance led by infection. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with infection because it currently carries approved-linked support. Linked drugs include RELEBACTAM. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Beta-lactamase as ChEMBL target CHEMBL5031, mapped to UniProt P24735. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Beta-lactamase
SINGLE PROTEIN · Pseudomonas aeruginosa (strain ATCC 15692 / PAO1 / 1C / PRS 101 / LMG12228)
As of 2026-09-13
ChEMBL target ID
CHEMBL5031
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P24735
Beta-lactamase
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Beta-lactamase is the right protein anchor across sources, using UniProt P24735 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why infection is currently framed as approved-linked support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameBeta-lactamase
Target TypeSINGLE PROTEIN
OrganismPseudomonas aeruginosa (strain ATCC 15692 / PAO1 / 1C / PRS 101 / LMG12228)
UniProtP24735
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelBeta-lactamase
UniProt AccessionP24735
Component TypeProtein
Sequence Length397 aa

Beta-lactamase

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Beta-lactamase, mapped to UniProt P24735. Sequence length is 397 aa.

Mapped IDP24735
Review nameBeta-lactamase
OrganismPseudomonas aeruginosa (strain ATCC 15692 / PAO1 / 1C / PRS 101 / LMG12228)
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Beta-lactamase shows approved-linked disease relevance led by infection. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
infection
1 linked drug · 1 direct · 1 efficacy
Linked drugRELEBACTAM
Approved-linked Approved
pyelonephritis
1 linked drug · 1 direct · 1 efficacy
Linked drugRELEBACTAM
Approved-linked Approved
urinary tract infection
1 linked drug · 1 direct · 1 efficacy
Linked drugRELEBACTAM
Late clinical Phase III
bacterial disease
1 linked drug · 1 direct · 1 efficacy
Linked drugRELEBACTAM
Late clinical Phase III
bacterial pneumonia
1 linked drug · 1 direct · 1 efficacy
Linked drugRELEBACTAM
Clinical signal Phase II
hematopoietic and lymphoid cell neoplasm
1 linked drug · 1 direct · 1 efficacy
Linked drugRELEBACTAM
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with infection because it currently carries approved-linked support. Linked drugs include RELEBACTAM. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseinfection
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

5
Approved
Assay Mix

Activity Type Distribution

IC50102.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL1795572 8.3 IC50 5.0 Preclinical
CHEMBL1795567 8.12 IC50 7.5 Preclinical
CHEMBL1795565 8.02 IC50 9.6 Preclinical
CHEMBL5409555 7.85 IC50 14.0 Preclinical
CHEMBL1795571 7.68 IC50 21.0 Preclinical
CHEMBL338157 7.62 IC50 24.0 Preclinical
CHEMBL338933 7.6 IC50 25.0 Preclinical
CHEMBL2079714 7.57 IC50 27.0 Preclinical
CHEMBL1795566 7.34 IC50 46.0 Preclinical
CHEMBL130187 7.32 IC50 48.0 Preclinical
Distribution

pChEMBL Value Distribution

11
5.0
20
5.5
21
6.0
7
6.5
5
7.0
5
7.5
3
8.0
0
8.5
0
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

AVIBACTAM
CHEMBL1689063
Approved 2015
Properties Compare Identifier
AVIBACTAM SODIUM
CHEMBL2107817
Approved 2015
Properties Compare Identifier
TAZOBACTAM
CHEMBL404
Approved 1993
Properties Compare Identifier
CLAVULANIC ACID
CHEMBL777
Approved 1984
Properties Compare Identifier
Assay Landscape

Assay Landscape

95
Total Assays
71
Tested Compounds
2
Assay Types
Binding — 93 assays, 71 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 93 71 6.1
Functional — 2 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 2 0 —

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine